Maxim Verlee

Mr. Maxim Verlee

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2021 in Genes
Verified
Journal Article
Open access
PDF file
MVMaxim Verlee
Maxim Verlee
ABAude Beyens
Aude Beyens
AGAlper Gezdirici
Alper Gezdirici
EGElif Yilmaz Gulec
Elif Yilmaz Gulec
LPLore Pottie
Lore Pottie
BCBert Callewaert
Bert Callewaert
Hereditary disorders of connective tissue (HDCT) compromise a heterogeneous group of diseases caused by pathogenic variants in genes encoding different components of the extracellular matrix and characterized by pleiotropic manifestations, mainly affecting the cutaneous, cardiovascular, and musculoskeletal systems. We report the case of a 9-year-old boy with a discernible connective tissue disorder characterized by cutis laxa (CL) and multiple herniations and caused by biallelic loss-of-function variants in EFEMP1. Hence, we identified EFEMP1 as a novel disease-causing gene in the CL spectrum, differentiating it from other HDCT.

1 April 2025 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
MVMaxim Verlee
Maxim Verlee
EDErika D’hAenens
Erika D’hAenens
LCLaurenz De Cock
Laurenz De Cock
LMLaura Muiño Mosquera
Laura Muiño Mosquera
KGKatya De Groote
Katya De Groote
BCBert Callewaert
Bert Callewaert

1 October 2026 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
MVMaxim Verlee
Maxim Verlee
MHMarrit M. Hitzert
Marrit M. Hitzert
RLRosa Laura van Loon
Rosa Laura van Loon
LMLaura Muiño Mosquera
Laura Muiño Mosquera
KGKatya De Groote
Katya De Groote
BCBert Callewaert
Bert Callewaert
BACKGROUND: Virtual panel analysis (VPA) of exome data is a common approach for the molecular diagnosis of congenital heart disease (CHD). However, differences in gene panel composition and patient inclusion criteria limit the evaluation of its diagnostic utility. This study aims to assess the diagnostic yield of VPA in a cohort of patients with CHD across 3 academic centers. METHODS: We collected clinical data including phenotypic features and family history, from 853 probands with CHD who underwent VPA analysis at the Center for Medical Genetics Ghent (525 probands; 471 genes), the University Medical Center Groningen (195 probands; 345 genes), and the University Medical Center Utrecht (133 probands; 55 genes). We evaluated the diagnostic yield by comparing the 3 centers with respect to panel composition and clinical presentation. RESULTS: The Center for Medical Genetics Ghent reported a higher diagnostic yield (9.9%) compared with the University Medical Center Groningen (7.2%) and the University Medical Center Utrecht (5.3%). In all centers, the diagnostic yield was higher in patients presenting with a syndromic constellation and did not differ significantly between the sporadic and familial cases. In 1.7% of the 536 nonsyndromic probands, a molecular cause was identified that typically is associated with syndromic CHD. Twelve genes showed likely pathogenic or pathogenic variants in multiple patients and contributed to 56.2% of the identified causes. CONCLUSIONS: We report an overall diagnostic yield of VPA for CHD of 8.6%, to which only a few genes contribute significantly, highlighting the complex origin of CHD. Since panel size, gene panel content, and local practices largely affect the diagnostic yield, we propose a (minimum) core gene panel for suspected isolated CHD, as well as a coordinated testing strategy for CHD to improve diagnosis and counseling and to catalyze collaborative efforts.

27 January 2025 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
MVMaxim Verlee
Maxim Verlee
EDErika D’hAenens
Erika D’hAenens
LCLaurenz De Cock
Laurenz De Cock
LMLaura Muiño Mosquera
Laura Muiño Mosquera
KGKatya De Groote
Katya De Groote
BCBert Callewaert
Bert Callewaert